Wah's Wonderful War Room | Wah Yan | Substack

The Ghost of Martin Shkreli?

Or 'why Amylyx's pricing & commercialization strategy for ALS drug RELYVRIO pushes key life science industry tensions into the spotlight'

Oct 1, 2022 •

New

Top

Community

Why Healthcare is a Squid Game

Or 'why healthcare stakeholders keep trying to punch each other in the face'

Sep 23, 2022 •

The Fog of War (for MFP)

Or 'possible futures for US price negotiation for pharmaceutical products & what you should do about it'

Sep 15, 2022 •

The $388 Billion Dollar Myth

Or 'why is it so hard to make pure-B2C / D2C in healthcare work'

Aug 14, 2022 •

The Kickstarter(s) of Biopharma

Or 'What's happening at the intersection of #web3 & life science R&D?'

Jul 27, 2022 •

So You Want To Be a Drug (and/or Medical Device) Lord

Or 'How to determine the vision for your life sciences venture'

Jun 26, 2022 •

The Minimally Viable Biopharma Infrastructure Model

Or 'why starting a biopharma company is like playing Zerg in StarCraft'

Jun 15, 2022 •

A Strategist's Personal Holiday

Or 'reflections on my career after starting my latest role'

May 2, 2022 •

Wah's Wonderful War Room

A strategist's journey through the healthcare industry.

Wah's Wonderful War Room

About Archive Sitemap

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts